Modulating Self‐Assembly of Amyloidogenic Proteins as a Therapeutic Approach for Neurodegenerative Diseases: Strategies and Mechanisms

@article{Liu2012ModulatingSO,
  title={Modulating Self‐Assembly of Amyloidogenic Proteins as a Therapeutic Approach for Neurodegenerative Diseases: Strategies and Mechanisms},
  author={Tingyu Liu and Gal Bitan},
  journal={ChemMedChem},
  year={2012},
  volume={7}
}
Abnormal protein assembly causes multiple devastating disorders in the central nervous system (CNS), such as Alzheimer’s, Parkinson’s, Huntington’s, and prion diseases. Due to the now extended human lifespan, these diseases have been increasing in prevalence, resulting in major public health problems and the associated financial difficulties worldwide. The wayward proteins that lead to disease self‐associate into neurotoxic oligomers and go on to form fibrillar polymers through multiple… Expand
Modulators of Amyloid β-Protein (Aβ) Self-Assembly
Abstract Amyloid β-protein (Aβ) is a small, natively unstructured protein with unknown physiological function. In Alzheimer’s disease (AD), Aβ self-assembles into metastable, toxic oligomers thatExpand
Modulators of amyloid protein aggregation and toxicity: EGCG and CLR01
Abnormal protein folding and self-assembly causes over 30 cureless human diseases for which no disease-modifying therapies are available. The common side to all these diseases is formation ofExpand
Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity.
TLDR
The strategy of using C-terminal fragments of A β as modulators of Aβ assembly is reviewed and the relevant challenges, therapeutic potential, and mechanisms of action of such fragments are discussed. Expand
Interactions between Curcumin Derivatives and Amyloid-β Fibrils: Insights from Molecular Dynamics Simulations
TLDR
Curcumin and a set of curcumin derivatives in complex with a hexamer peptide model of the Aβ1–42 fibril are investigated using nearly exhaustive docking, followed by multi-ns molecular dynamics simulations, to provide atomistic-detail insights into the molecules’ binding and inhibitory properties. Expand
Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin
TLDR
Doxycycline and EGCG were efficient in removing aggregates in pre‐clinical studies in a transgenic mouse model for transthyretin (TTR) systemic amyloidosis and represent an opportunity to address mechanisms and key players in deposit removal. Expand
Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro.
TLDR
The in vitro results show that ASS234 may have an impact on different processes involved in AD pathogenesis and provide evidences that it has encouraging attributes as a therapeutic lead compound. Expand
Discovery of Small Molecules that Induce the Degradation of Huntingtin.
TLDR
Two small hybrid molecules designed by linking a ligand for ubiquitin ligase with probes for mHtt aggregates reduced mHTT levels in HD patient fibroblasts and appear to be promising candidates for the development of a treatment for HD. Expand
Toxicity inhibitors protect lipid membranes from disruption by Aβ42.
TLDR
Interference with membrane interactions is an important factor for Aβ42 toxicity inhibitors and should be taken into account in potential therapeutic strategies, in addition to disruption or remodeling of amyloid assembly. Expand
Molecular tweezers for lysine and arginine - powerful inhibitors of pathologic protein aggregation.
TLDR
Specific host-guest chemistry between aggregation-prone proteins and lysine/arginine binders rescues cell viability and restores animal health in models of AD, PD, and TTR amyloidosis. Expand
Structure-activity relationships of sugar-based peptidomimetics as modulators of amyloid β-peptide early oligomerization and fibrillization.
TLDR
It is clearly demonstrated that molecules delaying the aggregation can stabilize the monomeric peptide or promote the formation of soluble oligomeric species, and molecules that accelerate the aggregating process can prevent the presence of small toxic oligomers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 320 REFERENCES
Strategies for the Inhibition of Protein Aggregation in Human Diseases
TLDR
An overview of potential strategies for tackling protein aggregation and its associated toxicity, focusing on protein aggregation in human disease is given. Expand
New Directions for Neurodegenerative Disease Therapy: Using Chemical Compounds to Boost the Formation of Mutant Protein Inclusions
TLDR
A compound is published, B2, which promotes the formation of large inclusions by mutant Huntingtin and α-synuclein, while rescuing some of the toxic effects of these proteins, which contradicts previous therapeutic approaches and supports growing evidence for the protective effects of inclusions. Expand
Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death
TLDR
A cell-culture model in which the neurons degenerate on induction of endogenous expression of Aβ/CTF of APP is established and these cultures have been used to test whether tricyclic pyrone compounds may prevent Aβ-CTF-mediated neuronal death, and results to date have been encouraging. Expand
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.
TLDR
It is demonstrated that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington's and Parkinson's diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. Expand
Baicalein Inhibits Formation of α‐Synuclein Oligomers within Living Cells and Prevents Aβ Peptide Fibrillation and Oligomerisation
Abnormal protein aggregation in the brain is linked to the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Recent studies revealed thatExpand
β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Lewy bodies (LBs) and Lewy neurites (LNs) in the brain constitute the main histopathological features of Parkinsons disease (PD) and dementia with Lewy bodies (DLB), and are comprised of amyloid-likeExpand
Inhibition of Alzheimer’s amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo
TLDR
The results suggest that CP2 might be beneficial to AD patients by preventing Aβ aggregation and disaggregating existing Aβ oligomers and protofibrils. Expand
Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies
TLDR
A paradigm shift is emerging that necessitates the reevaluation of the relative importance of polymeric (fibrillar) vs. oligomeric assemblies in the pathobiology of AD. Expand
A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid‐β oligomeric complexes
TLDR
A cell‐permeable tricyclic pyrone named CP2 is identified that ameliorates this toxicity of amyloid‐β protein and significantly reduces the levels of Aβ‐OCs. Expand
Tricyclic pyrone compounds prevent aggregation and reverse cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons
TLDR
TP compounds effectively inhibit aggregation caused by mhtt in neurons and glial cells and may be used as lead compounds for prevention or treatment of multiple neurodegenerative diseases including HD and AD. Expand
...
1
2
3
4
5
...